Attention Hospice Providers: Important Public Health Advisory
Posted by Dr. Julia Harder
The FDA is advising healthcare professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska manufacturing site. Due to problems that occurred when these products were packaged and labeled at the site, tablets from one product type may have carried over into packaging of another product. This could result in a stray pill of one medicine ending up in the bottle of another product.
The following products may be affected:
- Opana ER (oxymorphone extended-release)
- Opana (oxymorphone immediate-release)
- Oxymorphone (generic)
- Percocet (oxycodone/acetaminophen)
- Percodan (oxycodone/aspirin)
- Endocet (oxycodone/acetaminophen)
- Endodan (oxycodone/aspirin)
- Morphine sulfate extended-release (generic)
- Zydone (hydrocodone/acetaminophen)
The FDA advises patients and healthcare professionals to examine opiate medicines made by Endo in their possession and ensure that all tablets are the same. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program. Go to http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm to learn how to report.